PCSK9抑制剂在治疗家族性高胆固醇血症中的研究进展

Progress of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia

血脂异常与动脉粥样硬化性心血管疾病(ASCVD)的发生有密切联系。我国血脂异常的患病率高达18.6%,是心血管疾病的主要危险因素。其中,家族性高胆固醇血症(FH)是脂质代谢异常最严重的疾病之一,若未进行及时的药物干预和治疗,将大大增加心血管疾病发生率和死亡率。前蛋白转化酶枯草溶菌素9(PCSK9)是一种丝氨酸蛋白酶,可以结合并促进低密度脂蛋白受体(LDLR)的降解而导致LDL水平升高,PCSK9抑制剂治疗FH的高效性和安全性成为近几年的研究热点。本文对PCSK9抑制剂在治疗家族性高胆固醇血症中的研究进展予以综述。

Dyslipidemia is closely related to the occurrence of atherosclerotic cardiovascular disease(ASCVD).The prevalence of dyslipidemia in China is as high as 18.6%,which is the main risk factor of cardiovascular diseases.Familial hypercholesterolemia(FH)is one of the most serious diseases with abnormal lipid metabolism.Without timely drug intervention and treatment,it will greatly increase the incidence and mortality of cardiovascular diseases.Proprotein convertase subtilisin/kexin type 9(PCSK9)is a kind of serine protease,can combine and promote the degradation of low density lipoprotein receptor(LDLR)and result in higher LDL levels,the PCSK9 inhibitors for treatment of FH efficiency and safety become a hot research topic in recent years,this paper briefly summarized the PCSK9 inhibitor research progress in the treatment of familial hypercholesterolemia.